Bionano Announces Publication Showing OGM’s High Resolution Structural Variation Detection in Cancer Validated by Cas9-Directed Nanopore Sequencing
April 24 2024 - 8:00AM
Bionano Genomics, Inc. (Nasdaq: BNGO), today announced the
results of an implementation study conducted by researchers at
University Medical Center Groningen that compared optical genome
mapping (OGM) to traditional cytogenetic methods for the detection
of structural variants (SVs) in bone marrow aspirate (BMA) samples.
OGM has been shown to regularly detect SVs missed by other methods,
as a result of the higher resolution and sensitivity of OGM. Some
of OGM’s novel findings, however, are difficult for other methods
to validate, because of their resolution limitations. In this
paper, researchers used OGM to detect variants in the BMA samples
that were missed by traditional methods, and then applied targeted
Cas9-directed Nanopore sequencing to validate the variants detected
with OGM and define the breakpoints at the base pair level. The
study results highlight OGM’s ability to provide researchers with a
more comprehensive understanding of leukemia subtypes and the
potential of targeted Cas9-directed Nanopore sequencing to validate
new findings efficiently and at high resolution, compared to other
genome analysis methods, including short read or other long read
sequencing methods.
“We were pleased to see researchers conclude that the findings
detected by OGM in leukemia samples were robust and superior to
classical cytogenetic methods. When these findings are validated
with Cas9-directed Nanopore sequencing, we believe the result is a
powerful whole genome analysis tool that has the potential to
identify pathogenically relevant SVs and further our understanding
of molecular subtypes in blood cancer,” commented Erik Holmlin,
PhD, president and chief executive officer of Bionano.
The publication can be viewed here.
About Bionano
Bionano is a provider of genome analysis solutions that can
enable researchers and clinicians to reveal answers to challenging
questions in biology and medicine. The Company’s mission is to
transform the way the world sees the genome through OGM solutions,
diagnostic services and software. The Company offers OGM solutions
for applications across basic, translational and clinical research,
and nucleic acid extraction and purification solutions using
proprietary isotachophoresis (ITP) technology. Through
its Lineagen, Inc. d/b/a Bionano
Laboratories business, the Company also provides OGM-based
testing for certain laboratory developed tests. The Company also
offers an industry-leading, platform-agnostic software solution,
which integrates next-generation sequencing and microarray data
designed to provide analysis, visualization, interpretation and
reporting of copy number variants, single-nucleotide variants and
absence of heterozygosity across the genome in one consolidated
view. For more information, visit www.bionano.com
and www.bionanolaboratories.com.
Unless specifically noted otherwise, Bionano’s OGM products
are for research use only and not for use in diagnostic
procedures.
Forward-Looking Statements of Bionano
This press release contains forward-looking statements contains
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Words such as “ability,”
“believe,” “potential, “shown” and similar expressions (as well as
other words or expressions referencing future events, conditions or
circumstances and the negatives thereof) convey uncertainty of
future events or outcomes and are intended to identify these
forward-looking statements. Forward-looking statements include
statements regarding our intentions, beliefs, projections, outlook,
analyses or current expectations concerning, among other things:
the ability and utility of OGM to regularly detect SVs missed by
other cytogenetic methods; the ability and utility of Cas-9
directed LRS to validate SVs detected using OGM; the ability and
utility of OGM to detect SVs relevant to blood cancers; and other
statements that are not historical facts.
Each of these forward-looking statements involves risks and
uncertainties. Actual results or developments may differ materially
from those projected or implied in these forward-looking
statements. Factors that may cause such a difference include the
risks and uncertainties associated with: the impact of geopolitical
and macroeconomic developments, such as recent and future bank
failures, the ongoing conflicts between Ukraine and Russia and
Israel and Hamas, and related sanctions, and any global pandemics,
inflation, or supply disruptions, on our business and the global
economy; challenges inherent in developing, manufacturing and
commercializing products; our ability to further deploy new
products and applications and expand the markets for our technology
platforms; the failure of OGM to regularly detect SVs missed by
other cytogenetic methods; the failure of Cas-9 directed LRS to
validate SVs detected using OGM; the failure of OGM to detect SVs
relevant to blood cancers; future study results that contradict or
do not support the study results described in this press release;
our expectations and beliefs regarding future growth of the
business and the markets in which we operate; changes in our
strategic and commercial plans; our ability to obtain sufficient
financing to fund our strategic plans and commercialization
efforts; our ability to effectively manage our uses of cash, and
our ability to continue as a “going concern”; the ability of
institutions to obtain funding to support adoption or continued use
of our technologies; and including the risks and uncertainties
described in our filings with the Securities and Exchange
Commission, including, without limitation, our Annual Report on
Form 10-K for the year ended December 31, 2023 and in other filings
subsequently made by us with the Securities and Exchange
Commission. All forward-looking statements contained in this press
release speak only as of the date on which they were made and are
based on management’s assumptions and estimates as of such date. We
are under no duty to update any of these forward-looking statements
after the date they are made to conform these statements to actual
results or revised expectations, except as required by law. You
should, therefore, not rely on these forward-looking statements as
representing our views as of any date subsequent to the date the
statements are made. Moreover, except as required by law, neither
we nor any other person assumes responsibility for the accuracy and
completeness of the forward-looking statements contained in this
press release.
CONTACTS
Company Contact:Erik Holmlin, CEOBionano
Genomics, Inc.+1 (858) 888-7610eholmlin@bionano.com
Investor Relations:David HolmesGilmartin
Group+1 (858) 888-7625IR@bionano.com
Bionano Genomics (NASDAQ:BNGO)
Historical Stock Chart
From Jun 2024 to Jul 2024
Bionano Genomics (NASDAQ:BNGO)
Historical Stock Chart
From Jul 2023 to Jul 2024